3rd EBR Conference – Chat from Day 2

Comment: [Caroline Blaine] Link to study: https://europepmc.org/article/MED/31220609

Comment: [Caroline Blaine] If you have any questions for Arianne please add them here. Q and A will be straight after her presentation

Comment: [Malgorzata Bala] Q @AV: how was the clinically meaningful difference for LBP study defined - what was the basis?

Comment: [Malgorzata Bala] Q@AV: Do you think that adding Plain language summary as it is done in Cochrane (which is translated into other languages) may help in getting the message to the audience?

Comment: [Michaela Kosticova] Q to A: Have your findings about exercise for patients with knee osteoarthritis been implemented in clinical/physiotherapy guidelines?

Comment: [Malgorzata Bala] Q@ AV: What MInistry has done with the message?

Comment: [Malgorzata Bala] Q@AV: Do you think that language barier could be a reason for not getting the message to the researchers

Comment: [Caroline Blaine] Think twice study: https://pubmed.ncbi.nlm.nih.gov/32892192/

Comment: [Brunnhuber, Klara (ELS-LOW)] Q to Arianne: so how could these unnecessary unfunded studies be nipped in the bud? eg. through EBR requirements at trial registration?

Comment: [Mersiha] Here is where positive spin is needed :) Somehow these "finalized issues" have to stand out!

Comment: [Malgorzata Bala] Thank you for a great speech

Comment: [Mersiha] Fantastic work - thanks for excellent presentation!!!

Comment: [Caroline Blaine] https://pubmed.ncbi.nlm.nih.gov/8956711/

Comment: [Ayman Fahim] can we possibly have the presentation ??

Comment: [Hans Lund] All presentations available at our website: evbres.eu

Comment: [Caroline Blaine] All videos will be made available at evbres.eu after the conference (hopefully next week)

Comment: [Hans Lund] All can have a certificate if asking us

Comment: [Mersiha] Q @JS: placebo is unethical if there is efficient treatment? Efficient treatment is something that is top quality evidence like exercise for osteoarthritis: there are more ethical and less ethical placebos: where is the cut-off point?

Comment: [Caroline Blaine] Certificate of attendance will be emailed to all registered after the conference

Comment: [Malgorzata Bala] Comment: Since Systematic review in many countries is not recognised as a valid research design (just as any other review paper) that would require changing the status of the SR first

Comment: [Malgorzata Bala] But journals are a growing business - what would be their incentive to take part in such requirements

Comment: [Malgorzata Bala] Thank you for a great presentation and discussion!

Comment: [Maria E Marqués] Great discussion

11:00:37 From Jana Babjakova, SLOVAKIA : Looking forward for the next part ;-)

11:03:40 From Mersiha : Any questions for our speakers?

Please add them as „a comment to everyone“ on Zoom chat, start with „Q to ___“ so we know who it is for.

You can add a chat message during the talks & as many as possible will be answered during the Q&A at the end of the session.

11:04:15 From Caroline Blaine : https://evbres.eu/training-schools/

11:11:02 From Mersiha : If there are questions for Michaela, you can ask now :)

11:13:34 From Malgorzata Bala : Why do you think so many participants have not completed the modules?

11:13:48 From Marleen : Q to Michaela: The program looks impressive, congratulations! Currently, I experience this barrier: All materials I find, are too difficult for nurse assistants, but in nursing homes, almost every care is delivered by nursing assistants. Does M1 is suitable for nurse assistants?

11:15:08 From Malgorzata Bala : thank you

11:16:53 From Marleen : OK, that's useful, thanks.

11:17:05 From Jana Babjakova, SLOVAKIA : 👍

11:18:29 From Mersiha : excellent work Michaela, Jana & co :) thanks :)

11:20:55 From Malgorzata Bala : excellent work!

11:22:05 From Michaela Kosticova to Hosts and panelists : Please share the link to TS https://evbres.eu/training-schools/. The next TS will be open from 1st November.

11:22:38 From Mersiha : If there are questions about Limited use of systematic reviews when justifying new studies please feel free to ask :)

11:28:57 From Malgorzata Bala : Q: in view of prof Savulecu talk this morning have you looked at the ethical issues in new studies?

11:30:02 From Michaela Kosticova to Hosts and panelists : Could lack of awareness and knowledge of clinical researchers about SRs and EBR be one reason why there are so little refererrals to them?

11:33:12 From Malgorzata Bala : thank you

11:37:45 From Livia Puljak : :)

11:40:38 From Mersiha : Maybe new pyramid? With the "final verdict" at the top? 😳

11:42:50 From Mersiha : Carole will join us later today, for her Third presentation, and not now due to time zone: questions can be asked but will have to be answered later :)

11:59:37 From Malgorzata Bala : I also think that we still need to remember about making people aware of SR and what it is

11:59:56 From Mersiha : Definitely!

12:00:00 From Malgorzata Bala : and that is a type study something more valuable than Primary study for example for PhD or a part of it

12:00:11 From Hans Lund : Yes - that is the necessary basic knowledge

12:00:50 From Malgorzata Bala : 👏

12:01:26 From Malgorzata Bala : Thank you!

12:01:31 From Mersiha : Thanks for your attention! Have a nice lunch :)

13:40:18 From Michaela Kosticova : The program has been change. Now we have Lightning talk session. So please feel free to ask the questions

13:42:39 From Marleen : interesting idea!

13:42:55 From Prashanti : Very interesting

13:45:50 From Jana Babjakova, SLOVAKIA : Welcome to the session Lightning talks. Chair: Joanna Zajac, Co-chair: Jana Babjakova. You can use chat to ask your question: @Parisa, @ Alexandru, @Mersiha through their presentations.

13:51:54 From Brunnhuber, Klara (ELS-LOW) : Q to Mersiha: how did you identify the initially approached SR experts?

13:52:39 From Malgorzata Bala : @ Mersiha: Do you think it will be possible to have the whole SR done completely in an automatic way? There are many subjective judgements involved

13:53:29 From Malgorzata Bala : so we will not be out our jobs then

13:54:11 From Malgorzata Bala : have you had a Chance to contact any people involved in SR outside of healthcare

13:54:56 From Malgorzata Bala : still SR are not so popular in other fields

13:55:30 From Malgorzata Bala : also education would be important right?

13:55:39 From Brunnhuber, Klara (ELS-LOW) : Q to Mersiha: what next steps are you now planning?

13:56:57 From Caroline Blaine : Chat from yesterday now available on our website (at bottom of page)https://evbres.eu/abstractandprogram3/

13:57:29 From Mersiha : @Malgorzata education is quintessential!!

13:58:39 From Malgorzata Bala : yea, but I mean the filed of education - like schools

13:58:46 From Malgorzata Bala : they should also have more SR

13:58:49 From Mersiha : @Klara publication submitted 😉 let see what reviewers have to say 🙂

13:59:56 From Brunnhuber, Klara (ELS-LOW) : Thank you for your work, Mersiha, and hope to see more exciting studies coming out of your Working Group, even beyond EVBRES!

14:00:32 From Mersiha : @Malgorzata - definitely! More SRs education for undergraduates, postgraduates, nurses needed :)

14:01:25 From Hans Lund : Please, use the chat for questions for Jeremy

14:12:05 From Malgorzata Bala : Q @ Jeremy: some efforst have already been done to have more collaboration for example on HTA within Europe (INAHTA) but still it seems that each HTA

Agency works but itself. There are also language issues. How likely do you think it will be to have more collaborations as the one envisioned by Evidence Commission

14:13:33 From Brunnhuber, Klara (ELS-LOW) : Clarification Q for Jeremy: how do you define the term 'evidence intermediaries'?

14:15:01 From Judith ter Schure : Q to Jeremy: A take-away from yesterday's talk by Yuanxi Jia: Why do many new RCTs not cite an existing Cochrane review to motivate their trial; might be because Cochrane reviews are paywalled and/or they can't find them.

Do you see a better world in the future on paywalling of evidence synthesis coming out of the Evidence Commision project?

14:15:51 From Tina Poklepovic Pericic : Wonderful! Thanks very much, Jeremy.

14:20:14 From Malgorzata Bala : Thank you!

14:21:35 From Jeremy Grimshaw (he/him) to Hosts and panelists : @Judith ter Schure - we completely agree that open access to high quality evidence syntheses should be part of a high functioning global evidence support system (these are examples of global public goods).

14:23:58 From Hans Lund : Q to Alexandru: do you hope for a 100% automated screening - earlier tools assist the screening but never all

14:24:01 From Karen Robinson (she/her) : As a Canadian, I am curious to see Canada included in the flags associated with the European Space Agency :)

14:24:37 From Hans Lund : King Charles III is also King for Canada or…?

14:28:40 From Karen Robinson (she/her) : Other tools (such as PICO Portal, DistillerSR) use training (sets) from screeners. I don't think I heard that mentioned here (training on Wikipedia?). Could you clarify?

14:32:57 From Karen Robinson (she/her) : interesting talk - thank you!

14:33:43 From Prashanti : Interesting topic. :)

14:33:47 From Hans Lund : So good that people with your skills are working with these problems - Thx Alexandru

14:37:21 From Brunnhuber, Klara (ELS-LOW) : Q to Alexandru: Did I catch it correctly that you will make the fruits of your work available online for anyone to use? What's the timeframe for this?

14:37:42 From Alexandru Vasile to Hosts and panelists : To your question: in our team’s philosophy, this would be an ideal algorithm, one that can screen full text, not only title and abstract. This program would also be able to analyze graphs, images and other multimodal data.

14:38:33 From Alexandru Vasile to Hosts and panelists : To the question concerning the Canadian flag: it’s there but couldn’t be seen because of the teams interface that showed the live video stream in the bottom right

14:41:33 From Alexandru Vasile to Hosts and panelists : To the question concerning the pre-training set: in order to learn the structure if language (i.e. relationships between nouns and verbs etc.), we have chosen to train on Wikipedia and Bookcorpus for the sheer amount of data that

is needed to pre-train a transformer neural model. For the fine-tuning, we have used data outputted by our team of experts that consists of highly scientific text that was labeled.

14:44:18 From Alexandru Vasile to Hosts and panelists : For the question concerning the availability of this tool. It would certainly be available within ESA and this usually means all collaborating entities. But in my personal opinion it should be made available to anyone that has a need for it.

14:44:40 From Hans Lund : From Alexandru: For the question concerning the availability of this tool. It would certainly be available within ESA and this usually means all collaborating entities. But in my personal opinion it should be made available to anyone that has a need for it.

15:00:07 From Jana Babjakova, SLOVAKIA : Welcome to the session 4th Oral presentation, 3-4 pm. Chair: Tella Lanta, Co-chair: Jana Babjakova.

15:03:53 From Jana Babjakova, SLOVAKIA : You can use chat to ask your questions @Carole, @Prashanti through the presentations.

15:06:40 From Caroline Blaine : https://onlinelibrary.wiley.com/doi/full/10.1002/jrsm.1542

15:10:43 From Brunnhuber, Klara (ELS-LOW) : Q to Carole: in your definition, what could be the difference between identical overlap and replication?

15:16:04 From Brunnhuber, Klara (ELS-LOW) : Q to Carole: do you think that a tool could be developed that automates the classification and visualisation of overlap between overviews (or indeed between SRs), with option to drill down into the underlying body of evidence?

15:16:28 From Jana Babjakova, SLOVAKIA : Next presentation:Prashanti Eachempati

15:19:52 From Livia Puljak : Q to Carole: what was the inspiration for this definition of overlap and its different categories

15:20:15 From Malgorzata Bala : @Hans thank you

15:22:46 From Caroline Blaine : Please remember to complete the evaluation form. We very much appreciate all your feedback https://www.survey-xact.no/LinkCollector?key=AFP3G3AFU191

15:29:11 From Hans Lund : Q to Prashanti: what are the certainty of your taxonomy? To be used in other areas?

15:31:20 From Prashanti : https://gh.bmj.com/content/7/5/e008113

15:35:47 From Brunnhuber, Klara (ELS-LOW) : Q to Prashanti: Your framework helps to identify the uncertainties in a very granular manner - do you think its results in any given scenario should lead to a similarly granular approach to addressing the identified uncertainties?

15:36:02 From Jana Babjakova, SLOVAKIA : Prashanti thanks for interesting talk and disccusion

16:33:17 From Prashanti : Answer to Klara- Hi Klara. Yes we have given the exampls in the paper - https://gh.bmj.com/content/7/5/e008113

16:33:52 From Prashanti : A to Klara- I will be happy to discuss if you have any particular scenario in mind :)

16:35:43 From Karen Robinson (she/her) : Welcome to the last keynote session! Please add your questions and comments in chat.

16:46:59 From Judith ter Schure : Q to Jong-Wook: Do you think the field of the "negative" cumulative meta-analysis you showed ccould have agreed on a their smallest effect of clinical relevance, according to your clinical experience?

16:55:47 From Hans Lund : Q to Jong-Wook: Can you elaborate about the patients and clinicians experiences being included

16:59:07 From Judith ter Schure : Some comments from my experience as a statistician:

(1) P-value tresholds do not have to be arbitrary: a research field can agree on a lower alpha level if for example they require larger evidence to implement a new treatment, because they either have prior disbelief in the biological mechanism of the treatment, or the treatment comes with a large price (expensive/adverse events) such that you require more convincing evidence

(2) Prior elicitation is incredibly difficult to do. Have not met a single biostatistician that is managing that really; default priors are often used. In my own experience as a biostatistician, it is much easier to agree on an effect size of minimal clinical relevence with a field, and type-I error

(3) Conventional confidence intervals lose their validity (e.g. the 95% in the 95%-confidence interval) when repeatedly calculated in a cumulative meta-analysis, but anytime-valid confidence sequences would do the job in a cumulative meta-analysis. You can compare those to the smallest effect

16:59:11 From Hans Lund : Q to Jong-Wook: would the perspectives, values and preferences of end users of the planned new research as presented in qualitative evidence synthesis be used in the same way

16:59:19 From Judith ter Schure : These are just comments

17:03:07 From Malgorzata Bala : can you use utility values in such translations?

17:03:14 From Judith ter Schure : *(typo) (3) Conventional confidence intervals lose their validity (e.g. the 95% in the 95%-confidence interval) when repeatedly calculated in a cumulative meta-analysis, but anytime-valid confidence sequences do the job in ALL-IN meta-analysis. You can compare those to a smallest effect size of clinical relevance.

17:04:37 From Steven Cuadra : In your opinion (I mean to your knowledge) How the network (EBRN) has so far been working with collaborator from developing countries. I asked this because as you can imagine decision makers and regulators in developing countries are hard to reach with this kind of approach to support or not a new trial.

17:06:30 From Steven Cuadra : Thanks

17:07:13 From Karen Robinson (she/her) to Hosts and panelists : great job, Jong-Wook!!

17:07:30 From Hans Lund to Hosts and panelists : Very good presentation Jong-Wook ;o)

17:07:36 From Jong-Wook Ban to Hosts and panelists : Thank you!

17:14:49 From Karen Robinson (she/her) : Please add comments and questions for Mike in chat!

17:18:21 From Hans Lund : Q to Mike: The interpretation of the authors use of SRs in introduction and Discussion, can be difficult, as they use different ways to state what they did etc. - how did you and co-authors define the formulation of a good and bad answer?

17:22:42 From Hans Lund : Q to Mike: Do you think the lack of knowledge and skills related to SR and meta-analysis among clinical researchers could explain the results? In an earlier presentation to day (Arianne Verhagen) suggested that clinical researchers (authors of RCTs) may not be very skilled in SR and meta-analyses

17:24:21 From Caroline Blaine : Links to 1998, 2002, 2007, 2010 and 2013 studies can be found under Q4 here: https://evbres.eu/about/about-evidence-based-research-ebr/

17:26:35 From Hans Lund : Q to Mike Related to your conclusion from 2022: would you think that the solution is to move single studies to registers / repositories and the publications in the future is the SRs - and not single studies

17:26:38 From Steven Cuadra : Could registries of systematic reviews of clinical trials and registries of clinical trials play a role in promoting that the results of clinical trials be interpreted in the context of the totality of the available evidence, at the time of publication of clinical trials? For example, when registering the trial, information could be requested on whether or not it was based on a previous systematic review that contributed to the design.

17:28:15 From Judith ter Schure : Wonderful talk! I apologize, but have to leave now. Thanks for a great conference!

17:29:28 From Brunnhuber, Klara (ELS-LOW) : Q to Mike: did you check how many of the island RCTs could have cited an SR, and whether the SRs that were cited were the best ones they could have referred to?

17:37:42 From Hans Lund : You mention in 2015 Mike, that a qualitative study may be needed to understand as Malgorzata ask. Here is one possible study: https://doi.org/10.18261/issn.1892-2021-03-06

17:38:09 From Hans Lund : Herling SF, Jespersen KF, Møller AM. Reflections and practices of citing papers in health care science -a focus group study. Nordisk sygeplejeforskning. 2021;11(03):235-45.

17:47:11 From Benjamin Rouse : I think some of the issues with just plugging in the results of a new trial into a meta-analysis are that it skips independent critical appraisal and evaluation of heterogeneity the new trial may introduce.

17:55:57 From Hans Lund : Thank you Mike for your presentation and your work over the years

17:56:26 From Caroline Blaine : Please remember to complete this short evaluation form, your views are important to us when planning future EBR conferences https://www.survey-xact.no/LinkCollector?key=AFP3G3AFU191

17:56:38 From Steven Cuadra : Thanks great conferences

17:58:31 From Malgorzata Bala : 👏

17:58:32 From Karen Robinson (she/her) : congratulations, Mersiha!

17:58:42 From Hans Lund : Congrats Mersiha

17:58:51 From Malgorzata Bala : congratulations!

17:58:53 From Livia Puljak : 😍

17:59:23 From Jana Babjakova, SLOVAKIA : Congratulation Mersiha;-))))Thank you very much, it was Great;-)

17:59:23 From Tina Poklepovic Pericic : Congratulations, Mersiha!!!

17:59:35 From Maria E Marqués : Congrats Mersiha!!!

17:59:53 From Mersiha : Thank you!!!!

18:00:06 From Anders McIlquham-Schmidt : Congrats Mersiha

18:00:18 From Karen Robinson (she/her) : Congratulations, Judith!!

18:00:25 From Livia Puljak : 👏

18:00:32 From Maria E Marqués : Congrats Judith!

18:00:36 From Anders McIlquham-Schmidt : Congrats Judith

18:00:49 From Malgorzata Bala : Bravo Judith!👏

18:01:31 From Malgorzata Bala : Great job! Thank you to the organising committee!

18:01:53 From Malgorzata Bala : 👏👏👏👏👏

18:02:03 From Livia Puljak : 🏆

18:02:05 From Karen Robinson (she/her) : thank you, all!

18:02:15 From Prashanti : Thank you and congratulations to the winners

18:02:21 From Livia Puljak : Thanks Tina, great job

18:02:22 From Anders McIlquham-Schmidt : Thank you all for another great conference. See you next year.

18:02:36 From Jana Babjakova, SLOVAKIA to Hosts and panelists : 🥰 , thank you all...wish you all the best, take care ;-)

18:02:36 From Parisa Gazerani : Thanks very much for the excellent conference.

18:02:45 From joann : Thank you all! So goood Conference

18:02:50 From Parisa Gazerani : Congratulations to winners! Very well done.

18:03:06 From Karin Horneber : Great conference. Thank you

18:03:15 From Thale Åsli to Hosts and panelists : Thank you!!! excellent work :)

18:04:15 From Brunnhuber, Klara (ELS-LOW) : What a brilliant conference! Huge thank you to all who have helped make it a reality and most of all to our speakers and participants!!!

18:04:42 From Maria E Marqués : It's been amazing! Thank you all!

18:05:23 From Jana Babjakova, SLOVAKIA : 👍

18:05:54 From Liz Dore : Yes excellent conference thank you very much.

18:06:38 From Marie Österberg SBU : Great two Days,Interesting and Important! thank you from Stockholm Sweden and SBU

18:06:47 From Caroline Blaine : @evbres on twitter

18:06:57 From L. Susan Wieland : Fantastic conference, thank you!

18:07:03 From Caroline Blaine : carolineblaine@evbres.eu for newsletter subscription

18:07:07 From Steven Cuadra : One of the best conference I have ever been. Thank you so much

18:07:08 From Brunnhuber, Klara (ELS-LOW) : thank you, Hans and TIia!!!

18:07:15 From Caroline Blaine : Please remember to complete this short evaluation form, your views are important to us when planning future EBR conferences https://www.survey-xact.no/LinkCollector?key=AFP3G3AFU191

18:07:19 From Anders McIlquham-Schmidt : 👏